Spravato vs. Ketamine Therapy: What the Clinical Evidence Actually Shows

Spravato and Ketamine Therapy at a Glance

The differences between Spravato and racemic ketamine span both clinical and practical dimensions. The table below outlines the primary differences in formulation, regulatory status, and patient experience.

The sections below unpack each dimension with full citations and context. Different adverse event capture protocols exist between studies, such as protocol-driven solicitation versus patient-initiated reporting, which influences the reported side effect rates.

What's the Difference Between Spravato and Generic Ketamine?

Spravato is the brand name for esketamine, which is the S-enantiomer of ketamine delivered exclusively as a nasal spray. Generic ketamine is a racemic mixture containing both R-enantiomers and S-enantiomers. Racemic ketamine has been FDA-approved as an anesthetic since 1970 and has been listed on the World Health Organization List of Essential Medicines since 1985^3,4.

The molecular distinction between enantiomers influences how the medication interacts with NMDA receptors in the brain. Spravato received FDA approval specifically for treatment-resistant depression in 2019 and major depressive disorder with acute suicidal ideation in 2020, with the REMS requirements described above. In January 2025, the FDA additionally approved Spravato as a monotherapy for treatment-resistant depression in adults.

Ketamine is a Schedule III Controlled Substance. Spravato is approved both as an adjunct to an oral antidepressant and, for treatment-resistant depression, as a standalone monotherapy, whereas racemic ketamine can be prescribed as a standalone treatment or alongside existing medications at your provider's discretion.

• Formulation: Spravato isolates the S-enantiomer, while generic ketamine uses the complete racemic mixture.
• FDA Status: Spravato is approved for specific depressive disorders, while generic ketamine is approved as an anesthetic and prescribed off-label for mental health conditions.
• Delivery Methods: Spravato is only available as a nasal spray, whereas racemic ketamine is delivered via multiple administration routes including IV infusion, intramuscular injection, sublingual tablets, and subcutaneous injection.
• Setting Requirements: Spravato requires a REMS-certified clinic visit, while racemic ketamine can be administered in clinics or at home under clinical supervision.
• Indicated Conditions: Spravato targets treatment-resistant depression and suicidal ideation, while racemic ketamine is used for depression, anxiety, PTSD, and related conditions.

Though related, Spravato and racemic ketamine are distinct in formulation, delivery, setting, and indicated use.

What Do Spravato's FDA Trials Show About Effectiveness?

The FDA pivotal trial program for Spravato consisted of five Phase 3 trials and one maintenance trial. All of these studies evaluated esketamine as an adjunct to a newly initiated oral antidepressant, which is how Spravato was originally approved. The FDA's January 2025 monotherapy approval was based on subsequent clinical evidence not included in this section.

• TRANSFORM-1: With 346 patients enrolled, this study did not meet its primary efficacy endpoint⁶.
• TRANSFORM-2: Among 227 patients, this study met its primary endpoint, though the effect size was classified as small (Cohen's d = 0.30)⁷.
• TRANSFORM-3: Enrolling 138 elderly patients with treatment-resistant depression, this study also failed to meet its primary endpoint. It showed essentially zero effect in the subgroup aged 75 and older⁸.
• ASPIRE-1 and ASPIRE-2: Both trials met their primary efficacy endpoints of reducing depressive symptoms at 24 hours. The secondary suicidality endpoint, measured by CGI-SS-r, did not reach statistical significance^9,10.
• SUSTAIN-1: The maintenance trial showed a positive result using a randomized withdrawal design. Researchers have debated that specific methodology in the medical literature¹¹.

Of Spravato's five Phase 3 pivotal trials, only TRANSFORM-2 was unambiguously positive on its primary efficacy endpoint, and even that trial showed a small effect size. TRANSFORM-1 and TRANSFORM-3 failed their primary depression endpoints. ASPIRE-1 and ASPIRE-2 met their primary depression endpoints but failed to demonstrate specific anti-suicidal effect on the key secondary endpoint they were designed to test. The trial record is more mixed than the FDA-approved label alone might suggest, even though Spravato can be effective for many people. Readers evaluating effectiveness should consider the full trial portfolio rather than just the final approval decision.

What Does Head-to-Head Research Show About Racemic Ketamine vs. Esketamine?

Two independent analyses have directly compared racemic ketamine and esketamine, and both favor racemic ketamine on key outcomes.

• Bahji 2021 Meta-Analysis: Pooling 1,877 patients across 24 randomized controlled trials, this meta-analysis found racemic ketamine response rates were approximately 2.2 times higher than esketamine. Racemic remission rates were approximately 2.5 times higher, while esketamine had an 80 percent higher dropout rate¹².
• Correia-Melo 2020 Trial: In a direct head-to-head comparison of 63 patients, the two medications were non-inferior at 24 hours. At seven days, the MADRS difference of 6.3 points trended toward racemic ketamine showing a more prolonged therapeutic effect¹³.

The largest available meta-analysis and the only direct head-to-head trial both trend in the same direction. They favor racemic ketamine on response, remission, and tolerability. The data challenges the assumption that FDA approval equates to superiority, even though Spravato remains a valid option.

What Do Real-World Studies Show About Spravato vs. Ketamine Outcomes?

Outside of controlled trials, two large real-world studies using the PHQ-9 with comparable baseline severity offer a directional comparison of Spravato and racemic ketamine in routine practice.

Both real-world studies report PHQ-9 outcomes in clinically treated populations, allowing a directional comparison across modalities, though differences in study design, patient populations, and outcome measures limit strict equivalence.¹⁶

• Mathai 2024: Evaluating Mindbloom's at-home racemic ketamine protocol across 11,441 patients, this peer-reviewed analysis reported an 89 percent symptom improvement rate. The cohort achieved a 28.1 percent remission rate at four weeks and a 49 percent average reduction in symptoms (mean reduction of 7.6 points)¹.
• Spravato real-world outcomes: Among Spravato patients in routine practice, available data shows an 18.4 percent remission rate at three to six months and a 29 percent average reduction in depressive symptoms (mean reduction of 4.4 points).¹⁶

Both studies used the same instrument (PHQ-9), the same remission threshold (score under 5), and comparable baseline severity. The racemic ketamine cohort achieved higher remission in a shorter timeframe with a substantially larger sample. The consistency of direction across trial data, meta-analytic data, and real-world data strengthens the overall evidence pattern favoring racemic ketamine, though individual results may vary.

What Is the Success Rate of Spravato?

Available real-world data indicates an 18.4 percent remission rate for Spravato at three to six months.¹⁶ Response and remission are distinct metrics: response means meaningful symptom reduction, while remission means symptoms fall below a specific threshold.

In the TRANSFORM-2 trial, the esketamine arm showed a 69.3 percent response rate, but the placebo arm showed a 52 percent response. The difference attributable to esketamine specifically is narrower than the headline figure suggests⁷.

For comparison, a peer-reviewed study of 11,441 patients using Mindbloom's racemic ketamine protocol found that 89 percent of participants reported improvement in their symptoms. The cohort reported a 56.4 percent response rate and a 28.1 percent remission rate at four weeks¹. Spravato's success rate depends heavily on the metric, timeframe, and whether the adjunct antidepressant's contribution is isolated. Real-world remission data for Spravato is lower than the racemic ketamine comparator, and trial response rates include the effect of a co-initiated antidepressant.

What Are the Side Effects and Dropout Rates of Spravato vs. Ketamine?

Spravato and racemic ketamine differ substantially in reported side effect rates, though the gap partly reflects different measurement methodologies: protocol-driven solicitation in Spravato trials versus patient-initiated reporting in at-home ketamine studies. Abuse and dependence risk in supervised, sub-anesthetic protocols is low¹⁵. Racemic ketamine is prescribed off-label by licensed providers for depression, anxiety, PTSD, and related conditions. Off-label prescribing is a standard, legally accepted medical practice across psychiatry¹⁴.

• SUSTAIN-2: The long-term Spravato safety study of 802 patients reported dizziness in 32.9 percent of patients, dissociation in 27.6 percent, nausea in 25.1 percent, and headache in 24.9 percent. Approximately 9.5 percent discontinued due to adverse events, and the serious adverse event rate was 6.9 percent. Roughly 75 percent did not complete the one-year course².
• Mathai 2024: The study of Mindbloom's racemic ketamine protocol found approximately 4 to 5 percent of patients experienced any side effect per session. Fewer than 0.1 percent experienced serious adverse events, and 0.4 percent discontinued due to adverse events¹.

SUSTAIN-2 uses protocol-driven adverse event solicitation at every clinic visit over one year. The Mathai 2024 study uses patient-initiated reporting over a four-week treatment course. These methodological differences likely account for some of the gap in reported rates. The direction of difference is consistent across metrics, but readers should weigh the methodological differences when interpreting the magnitude of that difference.

How Do Spravato and Ketamine Compare on Cost, Insurance, and Access?

Spravato's cost is driven by its REMS requirements (described above), which add clinic overhead and a mandatory observation period to every session. Racemic ketamine therapy cost varies by practice and delivery method, and it is typically paid out of pocket with transparent pricing.

• Spravato: Requires a REMS-certified treatment center for every dose. It is typically covered by commercial insurance and Medicare Part B with prior authorization. Without coverage, per-course costs can be substantial, and patients must travel to a certified center for every session⁵.
• Racemic ketamine therapy: IV infusion clinics typically charge per session with no insurance coverage. At-home providers offer defined treatment frameworks with transparent pricing. Mindbloom's at-home ketamine therapy starts at $165 per session, with programs billed in monthly installments. A 6-session program is $215 per session, billed as $430 per month for three months. A 12-session program is $185 per session, and an 18-session program is $165 per session. Returning clients pay as little as $129 per session. All programs are HSA and FSA eligible. Mindbloom is approximately 70 percent more affordable per session than IV ketamine clinics. No travel is required for at-home options.

Spravato's insurance coverage can reduce out-of-pocket costs for patients with qualifying plans, which is a legitimate advantage. For patients without coverage, or those who prefer at-home treatment with transparent pricing and fewer logistical barriers, racemic ketamine therapy through a clinically managed program may be more accessible.

Which Treatment Is Right for You: Spravato or Ketamine Therapy?

The right choice depends on diagnosis, insurance status, treatment goals, logistical preferences, and health history, because Spravato and racemic ketamine differ in care model, access, and evidence profile. Both medications offer evidence-based pathways for symptom relief.

Spravato may be a better fit if:

• You have a treatment-resistant depression diagnosis and need an FDA-approved medication for insurance or medical documentation purposes.
• Your commercial or Medicare Part B plan covers Spravato, reducing your out-of-pocket cost.
• You prefer or require in-person clinical supervision for every session.
• A REMS-certified center is within reasonable travel distance.
• You are able to attend multiple in-clinic visits per week with two-hour observation periods.

Racemic ketamine therapy may be a better fit if:

• You are seeking treatment for depression, anxiety, PTSD, or related conditions regardless of prior medication history.
• You prefer at-home treatment or fewer logistical barriers.
• You want the formulation favored by head-to-head meta-analytic research on response, remission, and tolerability.
• You value transparent, predictable out-of-pocket pricing.
• You want a program that combines ketamine treatment with clinical oversight, coaching, and integration support.
• You want access to both sublingual and subcutaneous administration options.

Both options involve supervised ketamine treatment. The evidence, cost structure, and care model differ meaningfully. Reviewing the data in this article with your clinician can help you make an informed decision.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.